Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas

Phase 1

Completed

• Conditions: Adenocarcinoma

• Registration Number: NCT00051675
• Lead Sponsor: XOMA (US) LLC

Brief Summary

The purpose of this study is to evaluate the safety, immunogenicity, and tolerability of a monoclonal antibody administered subcutaneously in the treatment of advanced cancers of the ovary, breast, lung, prostate, colon or rectum that are either refractory to standard therapies or for which therapies that may potentially be of major benefit do not exist.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-07
• Study First Submitted: 2003-01-14
• Study First Submitted QC: 2003-01-15
• Study First Posted: 2003-01-16
• Study Completion: 2003-09
• Status Verified: 2004-09
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (1)

Jack D. Weiler Hospital of the Albert Einstein College of Medicine; 🇺🇸 Bronx, New York, United States